MiMedx Group, Inc (NASDAQ:MDXG) Receives Consensus Rating of “Moderate Buy” from Brokerages

MiMedx Group, Inc (NASDAQ:MDXG) has been assigned an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $8.50.

MDXG has been the subject of several recent analyst reports. Citizens Jmp dropped their target price on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a report on Thursday, April 30th. Wall Street Zen cut MiMedx Group from a “hold” rating to a “sell” rating in a report on Saturday, August 1st. Finally, Weiss Ratings restated a “sell (d)” rating on shares of MiMedx Group in a research report on Thursday.

MiMedx Group Price Performance

Shares of NASDAQ:MDXG opened at $4.27 on Monday. The company has a market capitalization of $622.40 million, a P/E ratio of 106.78 and a beta of 1.45. MiMedx Group has a 1-year low of $3.03 and a 1-year high of $7.97. The firm’s 50 day simple moving average is $4.04 and its two-hundred day simple moving average is $4.14. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.33 and a quick ratio of 4.79.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). The firm had revenue of $64.36 million during the quarter, compared to analysts’ expectations of $63.46 million. MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. Research analysts expect that MiMedx Group will post -0.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in MDXG. Sunbelt Securities Inc. purchased a new stake in MiMedx Group during the 1st quarter valued at approximately $42,000. E Fund Management Co. Ltd. bought a new stake in shares of MiMedx Group during the second quarter valued at approximately $45,000. Legal & General Group Plc purchased a new position in shares of MiMedx Group in the second quarter worth $45,000. Kemnay Advisory Services Inc. purchased a new position in shares of MiMedx Group in the fourth quarter worth $48,000. Finally, Williams & Novak LLC bought a new position in shares of MiMedx Group during the second quarter worth $53,000. 79.15% of the stock is owned by hedge funds and other institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.